Baker Bros. Advisors’s Phaxiam Therapeutics PHXM Stock Holding History
Bought
Maintained
Sold
Other funds holding PHXM
Baker Bros. Advisors's PHXM Position: Q4 2018 in Review
Baker Bros. Advisors sold out of Phaxiam Therapeutics (PHXM) in Q4 2018, closing a stake of 108,597 shares — an estimated $9.31M sold.
Baker Bros. Advisors first reported a position in PHXM in Q4 2017 and held it in 4 quarters. The position peaked at $68M in Q4 2017. 5 funds tracked by Wall St. Rank hold PHXM as of Q4 2018.
- Baker Bros. Advisors reported no remaining Phaxiam Therapeutics position as of Q4 2018 after selling out during the quarter.
- Baker Bros. Advisors sold 108,597 Phaxiam Therapeutics shares in Q4 2018, an estimated $9.31M.
- Baker Bros. Advisors first reported a position in Phaxiam Therapeutics in Q4 2017 and held it in 4 quarters.
- Baker Bros. Advisors's Phaxiam Therapeutics position peaked at $68M in Q4 2017.
- 5 funds tracked by Wall St. Rank held Phaxiam Therapeutics as of Q4 2018.
Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.